Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases

• ClinicalTrials.gov Identifier: NCT00540969
• Recruitment Status: Terminated
• First Posted: October 8, 2007
• Results First Posted: February 1, 2017
• Last Update Posted: November 21, 2018
• Sponsor: Alliance for Clinical Trials in Oncology
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Alliance for Clinical Trials in Oncology

Study Description

Brief Summary:

RATIONALE: Cryoablation kills cancer cells by freezing them. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. It is not yet known whether cryoablation is more effective than external-beam radiation therapy in treating painful bone metastases.

PURPOSE: This randomized phase III clinical trial is studying cryoablation to see how well it works compared with external-beam radiation therapy in treating patients with painful bone metastases.

Condition or disease	Intervention/treatment	Phase
Kidney Cancer; Melanoma (Skin); Metastatic Cancer; Pain; Unspecified Adult Solid Tumor, Protocol Specific	Procedure: cryosurgery; Radiation: radiation therapy	Phase 3

Detailed Description:

OBJECTIVES:

• To determine pain relief in cancer patients with painful metastatic disease involving bone following treatment with cryoablation as compared to radiotherapy (RT).
• To compare the impact on quality-of-life following cryoablation or RT in patients with painful metastatic disease as measured using the validated Brief Pain Inventory (BPI) and Short Form (SF)-8.
• To determine change in analgesic use following therapy.
• To determine the frequency and severity of complications following treatment of painful metastases involving bone with either cryoablation or RT.

OUTLINE: This is a multicenter study. Patients are stratified according to size of the indexing lesion (≤ 5 cm vs > 5 cm), location of the target lesion (pelvis vs extremity vs vertebral body vs other), primary cancer type (melanoma or renal cell carcinoma vs other), and severity of pain (i.e., worst pain score in the last 24-hour period) (4-6 vs 7-10). Patients are randomized to 1 of 2 treatment arms.

• Arm I (percutaneous cryoablation): Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.
• Arm II (external-beam radiotherapy): Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.

Patients are contacted via phone on days 1 and 4 post treatment, weekly in weeks 1-4, every 2 weeks in weeks 6-24, and then every four weeks in weeks 28-36. Patients undergo pain and pain interference with daily life assessment at baseline and at these time points. Patients who elect to have repeated treatment (either radiotherapy or cryoablation) within the first 6 weeks after the initial treatment are removed from the study. Patients who fail to achieve a 2-point reduction in worst or average pain (in a 24-hour period) during weeks 6-20 after initial treatment and patients who report a return of pain (i.e., pain ≥ the worst pain in a 24-hour period reported at baseline) for 2 consecutive time points are offered the alternative treatment (radiotherapy or cryoablation, whichever the patient was not randomized to receive at initial treatment)*.

NOTE: *Patients who refuse to receive the alternative treatment are taken off study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 3 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases
• Actual Study Start Date: February 2008
• Actual Primary Completion Date: January 2010
• Actual Study Completion Date: January 2010

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm I (percutaneous cryoablation); Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.	Procedure: cryosurgery; Patients undergo cryosurgery using guidance from CT scan or ultrasound
Active Comparator: Arm II (external-beam radiotherapy); Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.	Radiation: radiation therapy; Patients undergo radiotherapy for 1 week

Outcome Measures

Primary Outcome Measures :

1. Comparison of Pre- and Post-treatment Worst Pain in 24 Hours at Week 6 as Measured on the Numeric 0 to 10 Brief Pain Inventory (BPI) Scale [ Time Frame: at week 6 ]

Secondary Outcome Measures :

1. Average Difference in Pre- and Post-treatment Average Pain, Pain Relief, and Pain Interference Scores at Week 6 as Measured With the BPI [ Time Frame: at week 6 ]
2. Average Difference in Pre- and Post-treatment Physical (PCS-8) and Mental (MCS-8) Quality of Life at Week 6 as Measured by the 2 Subscales of the Short Form (SF)-8 [ Time Frame: at week 6 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

DISEASE CHARACTERISTICS:

Inclusion criteria:

• Histologically or cytologically confirmed solid tumor metastasis with index lesion involving or abutting bone

  • Index lesion with bone destruction is predominantly osteolytic in nature as assessed on CT imaging
  • If the nature of the metastatic disease has been previously documented, the index lesion to be treated does not require further documentation (i.e., biopsy)

• One primary painful metastatic site

  • Additional less painful metastatic sites may be present
• Worst pain in the last 24 hours must be ≥ 4 on a 0-10 numeric scale
• Current analgesic therapies have failed OR the patient is experiencing intolerable side effects
• Tumor is appropriate for radiotherapy as determined by the participating radiation oncologist and accessible for cryoablation as determined by the participating radiologists upon review of ultrasound, CT scan, X-ray, or MRI examinations
• Have completed chemotherapy, hormonal therapy, or bisphosphonate therapy ≥ 4 weeks prior to registration OR have developed pain or have persistent pain while on a stable chemotherapy, hormonal therapy, or bisphosphonate therapy regimen for a period of ≥ 4 weeks

Exclusion criteria:

• Index lesion causing clinical or radiographic evidence of spinal cord or cauda equina compression/effacement

• Index lesion involves the skull

  • Treatment of other painful lesions in patients with skull lesions is not excluded
• Index lesion has evidence of a pathologic fracture or impending fracture in weight-bearing bones (e.g., vertebral body, periacetabular region, femur, or tibia) with > 50% loss of cortical bone

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Life expectancy ≥ 2 months
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

• See Disease Characteristics
• No concurrent medication known to interfere with platelet function or coagulation (e.g., aspirin, ibuprofen, clopidogrel, or warfarin) and such medications have been discontinued for an appropriate time period based on the drug half-life and known activity (e.g., aspirin for 7 days) for patients randomized to receive cryoablation only
• Low molecular weight heparin preparations must be discontinued 8 hours prior to cryoablation
• At least 2 weeks since prior cytotoxic chemotherapy (for patients randomized to receive cryoablation only)

Exclusion criteria:

• Has undergone prior cryoablation or radiotherapy of the index lesion
• Prior radiopharmaceutical therapy completed ≤ 4 weeks prior to registration
• Initiation of new chemotherapy ≤ 4 weeks prior to registration
• Concurrent surgery involving the treated lesion
• Anticipated treatment of the index lesion that would require ice-ball formation within 0.5 cm of the spinal cord, brain, other critical nerve structure, large abdominal vessel such as the aorta or IVC, bowel, or bladder

Contacts and Locations

Locations

United States, Alabama

UAB Comprehensive Cancer Center

Birmingham, Alabama, United States, 35294

United States, Arizona

Mayo Clinic Scottsdale

Scottsdale, Arizona, United States, 85259-5499

United States, Florida

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States, 32224

United States, Michigan

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States, 48201-1379

United States, Minnesota

Mayo Clinic Cancer Center

Rochester, Minnesota, United States, 55905

United States, Wisconsin

Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center

Milwaukee, Wisconsin, United States, 53215

Medical College of Wisconsin Cancer Center

Milwaukee, Wisconsin, United States, 53226

Sponsors and Collaborators

Alliance for Clinical Trials in Oncology

National Cancer Institute (NCI)

Investigators

• Study Chair: Matthew R. Callstrom, MD, PhD; Mayo Clinic

More Information

• Responsible Party: Alliance for Clinical Trials in Oncology
• ClinicalTrials.gov Identifier: NCT00540969
• Other Study ID Numbers: NCCTG-N06C6; NCI-2009-00690 ( Registry Identifier: CTRP (Clinical Trials Reporting System) ); CDR0000570788 ( Registry Identifier: PDQ (Physician Data Query) )
• First Posted: October 8, 2007
• Results First Posted: February 1, 2017
• Last Update Posted: November 21, 2018
• Last Verified: October 2018

Keywords provided by Alliance for Clinical Trials in Oncology:

bone metastases; pain; unspecified adult solid tumor, protocol specific; stage IV melanoma; stage IV renal cell cancer

Additional relevant MeSH terms:

Melanoma; Neoplasm Metastasis; Kidney Neoplasms; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Neoplastic Processes; Pathologic Processes; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases